Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial

Eisen, T., Frangou, E., Oza, B. et al. (22 more authors) (2020) Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial. Journal of Clinical Oncology, 38 (34). pp. 4064-4075. ISSN 0732-183X

Abstract

Metadata

Authors/Creators:
  • Eisen, T.
  • Frangou, E.
  • Oza, B.
  • Ritchie, A.W.S.
  • Smith, B.
  • Kaplan, R.
  • Davis, I.D.
  • Stockler, M.R.
  • Albiges, L.
  • Escudier, B.
  • Larkin, J.
  • Bex, A.
  • Joniau, S.
  • Hancock, B.
  • Hermann, G.G.
  • Bellmunt, J.
  • Hodgkinson, E.
  • Stewart, G.D.
  • Barber, J.
  • Brown, J.
  • McMenemin, R.
  • Nathan, P.
  • Pickering, L.M.
  • Parmar, M.K.B.
  • Meade, A.
Copyright, Publisher and Additional Information: © 2020 by American Society of Clinical Oncology. Reproduced in accordance with the publisher's self-archiving policy.
Dates:
  • Accepted: 25 August 2020
  • Published (online): 14 October 2020
  • Published: 1 December 2020
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Sheffield Teaching Hospitals
Depositing User: Symplectic Sheffield
Date Deposited: 16 Feb 2021 13:59
Last Modified: 14 Oct 2021 00:38
Status: Published
Publisher: American Society of Clinical Oncology (ASCO)
Refereed: Yes
Identification Number: https://doi.org/10.1200/jco.20.01800

Share / Export

Statistics